Navigation Links
Hot Flushes Result of Estrogen Addiction
Date:3/26/2010

UBC Professor of Endocrinology Dr. Jerilynn C. Prior presents finding on estrogen addition and its treatment with progesterone at Women's Health Congress 2010 in Washington DC

Vancouver, Canada (PRWEB) March 26, 2010 -- A woman having a hot flush would fail a lie detector test. She may also be addicted to estrogen, according to Dr. Jerilynn C. Prior, author and Professor of Endocrinology at the University of British Columbia. Prior will be presenting on the idea of 'estrogen addiction' and its treatment with progesterone at the Women's Health Congress, 2010 in Washington, DC, held March 26 to 28 at the Crystal Gateway Marriott.

The positive lie detector test isn't because she's not telling the truth, but because "she's experiencing a massive release of brain chemicals that increases skin blood flow and changes her skin chemistry to produce a galvanic response, or positive lie detector test," explains Prior. "Integrating what we know about hot flushes has led to the hypothesis that the brain exposed to prolonged high estrogen levels reacts like the brain of an addict without a fix when estrogen levels drop. The best animal model of hot flushes is the heroin-addicted mouse."

The estrogen addiction idea fits with the reality that most estrogen-treated women who take it for hot flushes will experience an increased number and intensity of hot flushes and night sweats when they stop estrogen. Prior has found that progesterone helps women to gradually decrease and stop estrogen without a rebound increase in hot flushes (www.cemcor.ubc.ca "Stopping Estrogen").

"The importance of the estrogen addiction idea is that it explains how progestins or progesterone work to effectively treat hot flushes," says Prior. Estrogen and progesterone work together in every tissue of women's bodies she writes in the book she co-authored with Susan Baxter, The Estrogen Errors--Why Progesterone is Better for Women's Health.

A study in Neuropsychopharmacology (2004) shows that women are at greater risk for cocaine addiction than are men. "Estrogens increase the excitability of the brain and thus the risk for dependence or addiction. Progesterone, on the other hand, calms the brain and decreases anxiety," says Prior. Extensive animal research and some early human studies show that progesterone decreases drug craving and lessens the psychological and physiological effects of cocaine's "high."

Jerilynn C. Prior, MD, FRCPC, ABIM, ABEM, is a Professor of Medicine, Endocrinology at the University of British Columbia (Vancouver, Canada). She is the founder and Scientific Director of the Centre for Menstrual Cycle and Ovulation Research (CeMCOR http://www.cemcor.ubc.ca/) and has published over 120 peer-reviewed scientific articles in medical journals including The New England Journal of Medicine and Lancet. Prior is invited as a Visiting Lecturer at institutions across Canada and the US (including the New York Academy of Sciences and Harvard School of Public Health) as well as internationally. She is author of the award-finalist book, Estrogen's Storm Season--Stories of Perimenopause (CeMCOR, 2005, [reprinted 2007 Vancouver, Canada), and The Estrogen Errors--Why Progesterone is Better for Women's Health.

For more information or to interview Dr Prior, please contact Lori Smithers: lori(dot)smithers(at)vch(dot)ca (Dr Prior's assistant) 604-875-5927 or the Conference Media Center at 703-271-5181.

# # #

Read the full story at http://www.prweb.com/releases/2010/03/prweb3794464.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Guaranteed PR Results from Borough PR with the New ‘PRcheck'
2. Abbreviated Trials Yield Misleading Results: Study
3. Residency match results not encouraging for adults needing primary care
4. Dear Doctor Magazine Reveals Makeover Contest Winner's Results and Expands Contest to Include Additional Winners
5. MDS Reports First Quarter Fiscal 2010 Financial Results
6. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results
7. Late-stage melanoma results in economic burden
8. Patheon reports first quarter fiscal 2010 results
9. Omeros Corporation to Host Conference Call on Fourth Quarter and Full Year 2009 Results on March 31
10. Healthcare Trust of America, Inc. Announces Fourth Quarter and Year-End 2009 Financial Results
11. MedQuist Reports Results for the Fourth Quarter and 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hot Flushes Result of Estrogen Addiction 
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of the most ... touted to be the next revolution in our fight against this complex disease. One ... of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few ...
(Date:3/29/2017)... (PRWEB) , ... March 29, ... ... suburbs and South Hills of Pittsburgh now have easier access to the ... only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of ... Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over ... recently, the only option for on-premises installation of its Help System for SharePoint was ... install the system into the entire tenant. , The company recently released a ...
(Date:3/28/2017)... ... ... Tuesday, March 28, 2017, is the annual American Diabetes Association Alert Day, ... find out if they are at risk for developing Type 2 diabetes. In recognition ... by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower Crown Lights ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017   Royal Philips (NYSE: ... technology, and PathAI, a company that develops artificial ... aim to develop solutions that improve the precision ... other diseases. The partnership aims to build deep ... of artificial intelligence to be applied to massive ...
(Date:3/29/2017)... 2017 Neurim Pharmaceuticals ("Neurim") and ... exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... sleep disorders in children with Autism Spectrum Disorders (ASD) and neurogenetic ... for children. The collaboration with Exeltis will help increase ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... to their offering. ... The global patient safety and risk management software market is ... Patient safety has become a priority for almost all ... in the last decade and is currently on the verge of ...
Breaking Medicine Technology: